Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
- None.
- None.
The announcement by Bristol Myers Squibb regarding the pricing of a public offering of senior unsecured notes totaling $13 billion is a significant financial event that merits attention from various stakeholders, including investors and market analysts. The offering, which includes tranches with varying maturity dates ranging from 2026 to 2064, indicates a strategic move to raise capital for the company's proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc. and other general corporate purposes.
Assessing the impact of such a large-scale debt issue involves analyzing the creditworthiness of Bristol Myers Squibb and the potential influence on its balance sheet and interest expenses. The offered interest rates, which span from 4.900% to 5.650% depending on the tranche, suggest a competitive pricing strategy, likely reflecting the company's credit rating and the current interest rate environment. Investors should be aware that the success of this offering could lead to increased liquidity for the company but also a higher debt load, which could affect future financial flexibility.
Furthermore, the stipulation that the company must redeem the notes at 101% of their aggregate principal amount if the acquisition of Karuna does not occur by a specified date introduces a conditional element to the offering. This condition highlights a degree of risk for investors, as the potential redemption could impact the company's cash reserves. The involvement of prominent financial institutions as joint lead managers and book-running managers underscores the significance of the offering and could instill confidence in potential investors.
The strategic intent behind the offering of senior unsecured notes by Bristol Myers Squibb is to fund the cash consideration for the acquisitions of Karuna Therapeutics and RayzeBio. These acquisitions are poised to enhance Bristol Myers Squibb's portfolio in the biopharmaceutical sector. The market's reception of this news can be influenced by the perceived value of the acquisitions and the company's ability to integrate these new assets effectively.
From a market perspective, the addition of Karuna's and RayzeBio's pipelines could position Bristol Myers Squibb more favorably in competitive markets, such as neuroscience and oncology. However, the market will also be closely monitoring the company's post-acquisition performance, including any synergies realized and the impact on revenue growth. The scale of the note offering suggests that Bristol Myers Squibb is confident in the potential of these acquisitions to create value, but it is essential for market observers to consider the execution risks and the long-term return on investment.
Moreover, the fact that the offering is not conditioned upon the completion of the acquisitions indicates a forward-looking approach by the company, ensuring financial flexibility regardless of the outcomes of these specific deals. This could be interpreted as a prudent move by the company to maintain a strong financial position while pursuing strategic growth opportunities.
In the context of this transaction, the legal considerations are paramount, particularly due to the conditional redemption feature associated with the proposed acquisition of Karuna. This feature introduces a contractual obligation for Bristol Myers Squibb to redeem the notes under certain circumstances, which could serve as a protective measure for investors. It is important to note that the redemption clause is tied to a specific event, the completion of the acquisition, which is a common practice in such financial instruments to hedge against transactional uncertainties.
Additionally, the issuance is being conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC), which implies a level of regulatory compliance and due diligence that must be met. The availability of these documents on the SEC's EDGAR database provides transparency and allows for investor scrutiny. The involvement of high-profile underwriters further suggests that the offering has been structured to meet stringent legal and regulatory standards, which can be reassuring for the market participants.
Investors should be aware that the legal framework governing the offering includes provisions that protect their interests, but also that the complexity of such transactions requires thorough analysis of the terms and conditions disclosed in the prospectus and related documents.
Bristol Myers Squibb intends to use a portion of the net proceeds of the Offering to fund the cash consideration payable in connection with the previously announced proposed acquisitions of Karuna Therapeutics, Inc. (“Karuna”) and RayzeBio, Inc. (collectively, the “Acquisitions”) and the fees and expenses in connection therewith and with the Offering. Bristol Myers Squibb expects to use any remaining net proceeds from the Offering for general corporate purposes. The Offering is not conditioned upon the consummation of the Acquisitions; however, if Bristol Myers Squibb's acquisition of Karuna is not completed on or before the later of (i) June 30, 2025 and (ii) the date that is five business days after any later date to which the “End Date” as set forth in the merger agreement relating to acquisition of Karuna may be extended pursuant to its terms, or Bristol Myers Squibb notifies the trustee in respect of the Notes that it will not pursue consummation of the acquisition of Karuna, then Bristol Myers Squibb will be required to redeem all outstanding Notes, other than the 2034 Notes, the 2044 Notes, the 2054 Notes and the 2064 Notes, at a special mandatory redemption price equal to
Citigroup Global Markets Inc., BofA Securities, Inc., Wells Fargo Securities, LLC, and Mizuho Securities
The Offering of the Notes is being made pursuant to an effective shelf registration statement (including a prospectus and preliminary prospectus supplement) (File No. 333-261623) filed with the
This press release shall not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, the Notes or any other security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful.
Cautionary Notes on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the use of forward-looking terminology such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are likely to relate to, among other things, statements about the expected timing of completion of the Offering, the intended use of proceeds from the proposed Offering, the consummation of the Acquisitions and projections as to the anticipated benefits thereof and are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These risks, assumptions, uncertainties and other factors include, among others, that the conditions to completion of the Acquisitions are not satisfied or waived or that the Acquisitions are not completed within the anticipated timeline or at all. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2023, as updated by Bristol Myers Squibb’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this press release are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
corporatefinancial-news
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214420778/en/
For more information, contact:
Media:
media@bms.com
Investors:
investor.relations@bms.com
Source: Bristol Myers Squibb
FAQ
What is the purpose of Bristol Myers Squibb's (BMY) public offering of senior unsecured notes?
How much is the combined aggregate principal amount of the senior unsecured notes in Bristol Myers Squibb's (BMY) offering?
What will Bristol Myers Squibb (BMY) use the net proceeds from the offering for?
What happens if Bristol Myers Squibb (BMY) fails to complete the acquisition of Karuna by a specified date?
Who are the joint lead managers and book-running managers for Bristol Myers Squibb's (BMY) offering of senior unsecured notes?
